Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: Correlation of expression and clinical outcome at first disease recurrence

Cancer

Volumn 103, Issue 5, 2005, Pages 1054-1063

  Wu, Shuling ^a,b   Geßner, Reinhard ^a   Von Stackelberg, Arend ^a   Kirchner, Renate ^a   Henze, Guenter ^a   Seeger, Karl ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukemia; Cytokine receptor expression; Disease recurrence; Prognosis

Indexed keywords

ANTILEUKEMIC AGENT; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 18; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; PROTEIN P40; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOFLUORESCENCE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADOLESCENT; BONE MARROW; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; CYTOKINES; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 13944277663     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20869     Document Type: Article

References (46)

1. Williams J. STAT signalling in cell proliferation and in development. Curr Opin Genet Dev. 2000;10:503-507.
2. Young P. Pharmacological modulation of cytokine action and production through signaling pathways. Cytokine Growth Factor Rev. 1998;9:239-257.
3. Callard R, George AJ, Stark J. Cytokines, chaos, and complexity. Immunity. 1999;11:507-513.
4. Hunter C, Reiner S. Cytokines and T cells in host defense. Curr Opin Immunol. 2000;12:413-418.
5. Akashi K, Traver D, Kondo M, et al. Lymphoid development from hematopoietic stem cells. Int J Hematol. 1999;69:217-226.
6. Baird AM, Gerstein RM, Berg LJ. The role of cytokine receptor signaling in lymphocyte development. Curr Opin Immunol. 1999;11:157-166.
7. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96:2022-2036.
8. Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci USA. 1996;93: 4742-4749.
9. Goyal RK, Longmore GD. Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production. Ann Med. 1999;31:208-216.
10. Moqattash S, Lutton JD. Leukemia cells and the cytokine network. Proc Soc Exp Biol Med. 1998;219:8-27.
11. Ivanoff J, Ivanoff A, Sundqvist K. Defective chemokine production in T-leukemia cell lines and its possible functional role. Dev Immunol. 2000;7:67-75.
12. Wu S, Korte A, Gessner R, et al. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence. Cancer. 2003;98:624-631.
13. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
14. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
15. Fayad L, Keating M, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256-263.
16. Pui CH. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol. 1998;5:292-301.
17. Henze G, von Stackelberg A. Treatment of relapsed childhood acute lymphoblastic leukemia. In: Pui CH, editor. Treatment of acute leukemias. New directions for clinical research. Totowa, NJ: Human Press; 2002:199-219.
18. Henze G, Fengler R, Hartmann R, et al. BFM group treatment results in relapsed childhood acute lymphoblastic leukemia. Hamatol Bluttransfus. 1990;33:619-626.
19. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood. 1991;78: 1166-1172.
20. Henze G, Fengler R, Hartmann R. Chemotherapy for relapsed childhood acute lymphoblastic leukemia: results of the BFM study Group. Hamatol Bluttransfus. 1994;36:374-379.
21. Buhrer C, Hartmann R, Fengler R, et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1993;21:470-476.
22. Kebelmann-Betzing C, Korner G, Badiali L, et al. Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor ALL. Cytokine. 2001;13:39-50.
23. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
24. Overbergh D, Valckx M, Waer and Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 1999;11:305-312.
25. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumaan C. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology. J Immunol Methods. 2000;246:79-90.
26. Stordeur P, Poulin LF, Craciun L, et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods. 2002; 259:55-64.
27. Zhang W, Knieling G, Vohwinkel G, et al. Origin of stroma cells in long-term bone marrow cultures from patients with acute myeloid leukemia. Ann Hematol. 1999;78:305-314.
28. Seeger K, Adams HP, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood. 1998;91:1716-1722.
29. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today. 1997;8:343-350.
30. Freedman MH, Grunberger T, Correa P, Axelrad AA, Dube ID, Cohen A. Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells. Blood. 1993;81:3068-3075.
31. Mori N, Shirakawa F, Murakami S, et al. Interleukin-1 alpha as an autocrine growth factor for acute lymphoblastic leukaemia cells. Br J Haematol. 1994;86:386-388.
32. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
33. Lotem J, Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene. 2002;21:3284-3294.
34. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest. 1994;93:424-428.
35. Masood R, Zhang Y, Bond MW, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood. 1995;85:3423-3430.
36. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA. 1992;89:1890-1893.
37. McDonald PP, Russo MP, Ferrini S, et al. Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils. Blood. 1998;92:4828-4835.
38. Di Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood. 1994; 84:220-228.
39. Giri JG, Kumaki S, Ahdieh M, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995;14:3654-3663.
40. Lodolce J, Burkett P, Koka R, et al. Interleukin-15 and the regulation of lymphoid homeostasis. Mol Immunol. 2002;39: 537-544.
41. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780.
42. Trentin L, Cerutti A, Zambello R, et al. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood. 1996;87:3327-3335.
43. Tinhofer I, Marschitz I, Henn T, et al. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000;95:610-618.
44. Anether G, Marschitz I, Tinhofer I, et al. Interleukin-15 as a potential costimulatory cytokine in CD 154 gene therapy of chronic lymphocytic leukemia. Blood. 2002;99:722-723.
45. Zheng Z, Takahashi M, Aoki S. Expression patterns of Co-stimulatory molecules on cells derived from human hematological malignancies. J Exp Clin Cancer Res. 1998;17:251-258.
46. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.